Author

JM Reese

Observed name: J Reese

Institutions: University of Utah, Innocrin Pharmaceuticals (United States), University of Colorado Anschutz

Observed institutions: Translational Genomics Research Institute, Mayo Clinic, University of Utah, Cancer Research UK, Innocrin Pharmaceuticals (United States), University Hospitals Seidman Cancer Center, Mayo Clinic in Arizona, University of Pittsburgh Medical Center, Case Comprehensive Cancer Center, University of Colorado Anschutz

OpenAlex ID: A5044800673

Abstract P5-05-05: Targeting the androgen receptor with seviteronel, a CYP17 lyase and AR inhibitor, in triple negative breast cancer

2019 · JM Reese, BL Babbs, et al. · Cancer Research · 5

Abstract P3-07-20: Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target

2017 · JM Reese, ES Bruinsma, et al. · Cancer Research · 1

Abstract P5-04-04: Activation of ERβ in triple negative breast cancer results in cell cycle arrest

2017 · JM Reese, ES Bruinsma, et al. · Cancer Research

Abstract OT1-01-02: Pilot trial of a type I polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer

2016 · J Baar, W Storkus, et al. · Cancer Research

Abstract P6-04-03: ERb and breast cancer: A potential predictive and prognostic biomarker and novel therapeutic drug target

2013 · JR Hawse, M Subramaniam, et al. · Cancer Research

Works count: 5

Citation count: 6

H-index: 1

I10-index: